The effect of intermittent inflation of an arm tourniquet (remote ischaemic preconditioning) on patient outcomes after surgery for intra-abdominal cancer (RIPCa) - a pilot study

Remote Ischaemic Preconditioning in intra-abdominal Cancer surgery (RIPCa) – a pilot study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN11439947

Enrollment

Registered

2021-10-26

Start date

2019-04-26

Completion date

Unknown

Last updated

2023-06-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elective surgery for intra-abdominal cancer Surgery Elective surgery for intra-abdominal cancer

Interventions

Participants allocated to the intervention group will receive remote ischaemic preconditioning (RIPC) in the anaesthetic room after induction of general anaesthesia and prior to skin incision. RIPC wi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Adults 18 years or over undergoing elective surgery for intra-abdominal cancer (colorectal, pancreatic or gynaecological) under general anaesthesia, and at increased risk of postoperative complications, as defined by the American College of Surgeons National Surgical Quality Improvement Project (ACS NSQIP) calculated risk of morbidity >10%

Exclusion criteria

Exclusion criteria: 1. Patients unable to give consent 2. Day surgery 3. Emergency surgery 4. Total intravenous anaesthesia 5. Pregnancy 6. Recent (< 1 month) or ongoing acute myocardial infarction 7. Unstable or ongoing angina 8. Peripheral vascular disease 9. History of vascular intervention in the limb to be used for RIPC 10. Thromboembolic disease 11. Significant coagulopathy or bleeding diathesis 12. Sickle cell disease 13. Neuromuscular diseases 14. Use of sulfonylureas or nicorandil

Design outcomes

Primary

Measure	Time frame
Feasibility of substantive trial measured using the recruitment rate of 50 participants over 12 months. Feasibility assessment will include the proportion of potentially eligible patients that are recruited to the study and followed up at the specified timepoints (days 2, 3, 5 30, 90, 180) and the proportion of required blood and urine samples that are collected and analysed.	—

Secondary

Measure	Time frame
1. Postoperative morbidity (as defined by Postoperative Morbidity Survey or POMS on days 2, 3, and 5 and the American College of Surgeons National Safety Quality Improvement Program or ACS NSQIP within 30 days, 90 days and 6 months postoperatively). 2. High sensitivity Troponin pre-operatively and on the first postoperative day 3. Renal stress biomarkers (urinary TIMP-2 * IGFBP-7) measured at 4 hours postoperatively 4. Hospital length of stay 5. Quality of life measured using the EQ-5D-5L questionnaire 6. Acceptability of the study assessed at the out of hospital follow-up	—

Measure

Time frame

1. Postoperative morbidity (as defined by Postoperative Morbidity Survey or POMS on days 2, 3, and 5 and the American College of Surgeons National Safety Quality Improvement Program or ACS NSQIP within 30 days, 90 days and 6 months postoperatively). 2. High sensitivity Troponin pre-operatively and on the first postoperative day 3. Renal stress biomarkers (urinary TIMP-2 * IGFBP-7) measured at 4 hours postoperatively 4. Hospital length of stay 5. Quality of life measured using the EQ-5D-5L questionnaire 6. Acceptability of the study assessed at the out of hospital follow-up

—

Countries

England, United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026